Research results and mechanism of sodium glucose cotransporter 2 inhibitors in the treatment of heart failure
10.3760/cma.j.cn431274-20210225-00221
- VernacularTitle:钠-葡萄糖共转运蛋白2抑制剂治疗心力衰竭的研究进展及机制探讨
- Author:
Huahua HUANG
1
;
Tao TIAN
;
Dongmei ZHANG
;
Wengyuan MA
Author Information
1. 山东第一医科大学，济南 250024
- Keywords:
Diabetes mellitus, type 2;
Heart failure;
Sodium-glucose cotransporter 2 inhibitor
- From:
Journal of Chinese Physician
2022;24(4):637-640,F3
- CountryChina
- Language:Chinese
-
Abstract:
Sodium glucose cotransporter 2 inhibitor (SGLT2i) emerged as a new hypoglycemic agent, which can inhibit glucose reabsorption and thus play a hypoglycemic role. Recent studies have shown that SGLT2i not only lowers blood glucose, but also has a protective effect on the cardiovascular system, which may benefit patients with heart failure.The specific mechanism of action is still not fully elucidated. This paper aims to summarize the latest research results of SGLT2i in the treatment of heart failure, and analyze the possible mechanisms for clinical guidance.
